Aptose Biosciences Inc. (TSX: APS)

Market Cap	26.26M
Revenue (ttm)	n/a
Net Income (ttm)	-64.24M
Shares Out	16.29M
EPS (ttm)	-2,124.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,500
Open	1.630
Previous Close	1.630
Day's Range	1.580 - 1.630
52-Week Range	1.580 - 9.900
Beta	1.47
Analysts	n/a
Price Target	31.02 (+1,826.71%)
Earnings Date	May 14, 2024

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. William G. Rice Ph.D.
• Country: Canada
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: APS

Financial Performance

Financial numbers in USD